Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
longxuetongluo
- Development stage
- Unknown
- Lead developer
- Jiangsu Kanion Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Longxuetongluo (LTC) is a pharmaceutical capsule derived from the total phenolic compounds of Chinese dragon’s blood (the red resin of Dracaena cochinchinensis). It is approved in China for the treatment of ischemic stroke during the convalescence stage. The main active ingredients are phenolic compounds such as loureirin A and loureirin C. Mechanistically, LTC exerts neuroprotective effects by inhibiting neuroinflammation—specifically suppressing nitric oxide (NO) and prostaglandin E2 (PGE2) production through downregulation of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2), as well as reducing pro-inflammatory cytokines like IL-1β, IL-6, and TNF-α. Metabolomics studies indicate that LTC modulates glycerophospholipid and sphingolipid metabolism pathways relevant to neuronal protection after ischemic injury[1][3][5]. It also demonstrates antiatherosclerotic effects[4].
- Brand names
- LongxuetongluoLongxue Tongluo CapsuleLTC
- Other names
- Longxuetongluo capsuleLongxue Tongluo CapsuleLTC
02
Targets
PTGS2 (Prostaglandin-Endoperoxide Synthase 2)NOS2 (Nitric Oxide Synthase 2)
Beyond the preview
Go deeper on longxuetongluo.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on longxuetongluo.